News Releases | Galecto

Year

23 Nov, 2020

Galecto Appoints Experienced Healthcare Executive Jayson Dallas to Board of Directors

Has extensive experience in pharma and biotech in U.S., Europe and globally Galecto completed U.S. initial public offering and plans to initiate three Phase 2 trials in the coming months BOSTON and COPENHAGEN, Denmark, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Galecto, Inc.

28 Oct, 2020

Galecto Announces Pricing of Initial Public Offering

BOSTON and COPENHAGEN, Denmark, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company developing therapeutics that are designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related

25 Sep, 2020

Galecto Raises $64 Million to Accelerate Development of Clinical Pipeline

Funds will support preparations for potential EU conditional approval of GB0139 in IPF and multiple new Phase 2 clinical trials Boston, MA/Copenhagen, Denmark, September 25, 2020 – Galecto, Inc., a privately-held biotechnology company focused on the development of novel treatments for fibrosis and

15 Sep, 2020

Galecto’s Oral Galectin-3 Inhibitor GB1211 Well Tolerated in Phase I Clinical Data Presented Recently at Several Scientific Conferences

GB1211, a potent oral small molecule galectin-3 inhibitor was well tolerated in human volunteer studies Phase 2a study planned to establish the anti-fibrotic effects of GB1211 in grade 2 to 4 Non-Alcoholic SteatoHepatitis (NASH) Data presented at the American Chemical Society Meeting, Drug

27 Aug, 2020

Galecto, Inc. Receives U.S. and EU Orphan Drug Designations for GB0139 in Idiopathic Pulmonary Fibrosis

The EMA cited GB0139’s clinically relevant biomarker data in IPF patients Significant reduction of YKL-40 biomarker in fibrosis, inflammation, tissue remodeling diseases Boston, MA/Copenhagen, Denmark, August 27, 2020 – Galecto, Inc., a privately-held biotechnology company focused on the

19 May, 2020

Galecto Appoints New Chair and Strengthens Board of Directors

Appoints Amit Munshi as Chair, deeply experienced industry executive, CEO of Arena Pharmaceuticals Succeeds Magnus Persson, who oversaw period of rapid growth and success for Galecto Appoints David Shapiro MD, former CMO of Intercept Pharmaceuticals, to Board of Directors Boston, MA/Copenhagen,

06 May, 2020

Galecto Advances Phase 2b Study of GB0139 in Idiopathic Pulmonary Fibrosis; Recruitment Remains on Track Despite COVID-19 Crisis

Recruitment on track in international “GALACTIC-1” Phase 2b IPF study Over 150 patients recruited to date with data readout expected in 2022 Galecto continues to build strong portfolio in fibrosis and cancer Boston, MA/Copenhagen, Denmark, May 6, 2020 – Galecto, Inc., a privately-held

04 May, 2020

Galecto presents GB0139 preclinical and clinical data on anti-fibrotic activity as online Experimental Biology 2020 poster

GB0139 showed pharmacodynamic evidence with reduction of galectin-3 Direct link to clinical results in IPF patients after 14 days treatment Lead compound being developed in Phase 2b trial, with readout due in 2022 Copenhagen, Denmark, May 4, 2020 – Galecto, Inc., a privately-held biotechnology

27 Apr, 2020

Galecto Appoints Jonathan Freve as Chief Financial Officer

Copenhagen, Denmark, April 27, 2020 – Galecto, Inc., a privately-held biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced the appointment of Jonathan Freve, CPA, as its Chief Financial Officer (CFO).

03 Feb, 2020

Galecto Appoints Industry Leader Bertil Lindmark, MD, PhD, as Chief Medical Officer

Dr. Lindmark brings broad R&D expertise, particularly in respiratory and inflammation Appointment reinforces Galecto’s ambition to be a global player following PharmAkea merger Copenhagen, Denmark, February 3, 2020 – Galecto, Inc., a leading developer of novel treatments for fibrosis and cancer,

Pagination

Current page 1
Page 2
Next page
Last page